3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
29
Lymphoma, Non-Hodgkin
8
Lymphoma, B-Cell
7
Lymphoma
5
Lymphoma, Follicular
4
Recurrence
3
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Dendritic Cell Sarcoma, Interdigitating
2
Burkitt Lymphoma
2
Neoplasms
1
Lymphoma, Mantle-Cell
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
31
fludarabine
28
Whole-Body Irradiation
18
Mycophenolic Acid
18
venetoclax
14
Tacrolimus
14
fludarabine phosphate
13
Standard of Care
13
Specimen Handling
10
Practice Guidelines as Topic
10
Melphalan
10
Busulfan
10
Sirolimus
9
Thiotepa
8
Interviews as Topic
8
Azacitidine
8
Educational Status
7
trametinib
6
Surveys and Questionnaires
6
Methods
6
Mesna
6
Biopsy
6
thymoglobulin
5
Rituximab
5
Magnetic Resonance Spectroscopy
5
Filgrastim
5
Early Intervention, Educational
5
Behavior Therapy
5
Antilymphocyte Serum
5
Peripheral Blood Stem Cell Transplantation
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
polatuzumab vedotin
×
1 year
×
Clear all
NCT04844866
2026-04-29
DALY 2-EU
Miltenyi Biomedicine GmbH
Phase 2
Recruiting
213 enrolled